SELLAS Life Sciences Group, Inc. SLS Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about SELLAS Life Sciences Group, Inc.'s operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is SELLAS Life Sciences Group, Inc.'s operating lease right-of-use asset amortization?
- SELLAS Life Sciences Group, Inc. (SLS) reported operating lease right-of-use asset amortization of $153K in Q1 2026.
- How has SELLAS Life Sciences Group, Inc.'s operating lease right-of-use asset amortization changed year-over-year?
- SELLAS Life Sciences Group, Inc.'s operating lease right-of-use asset amortization increased by 4.1% year-over-year, from $147K to $153K.
- What is the long-term trend for SELLAS Life Sciences Group, Inc.'s operating lease right-of-use asset amortization?
- Over 3 years (2022 to 2025), SELLAS Life Sciences Group, Inc.'s operating lease right-of-use asset amortization has grown at a 9.3% compound annual growth rate (CAGR), from $457K to $597K.